Clinical Benefit of American College of Chest Physicians versus European Society of Cardiology Guidelines for Stroke Prophylaxis in Atrial Fibrillation

Journal of General Internal Medicine

Volumn 30, Issue 6, 2015, Pages 777-782

  Andrade, Ambar A ^a   Li, Juan ^b   Radford, Martha J ^c   Nilasena, David S ^a   Gage, Brian F ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY   (United States)

^c Centers for Medicare/Medicaid Serv   (United States)

Author keywords

atrial fibrillation; epidemiology; outcomes; stroke; thromboembolism

Indexed keywords

WARFARIN; ANTICOAGULANT AGENT;

AGED; ANTICOAGULANT THERAPY; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CHADS2 SCORE; CONTROLLED STUDY; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEMATURIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MEDICAL SOCIETY; MEDICARE; PHYSICIAN; PRACTICE GUIDELINE; EUROPE; HEMORRHAGE; REGISTER; RISK FACTOR; STANDARDS; STROKE; UNITED STATES;

AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; EUROPE; FEMALE; HEMORRHAGE; HUMANS; MALE; PRACTICE GUIDELINES AS TOPIC; REGISTRIES; RISK FACTORS; SOCIETIES, MEDICAL; STROKE; UNITED STATES; WARFARIN;

EID: 84929841254     PISSN: 08848734     EISSN: 15251497     Source Type: Journal    
DOI: 10.1007/s11606-015-3201-1     Document Type: Article

References (36)

1. You JJ, Singer DE, Howard PA, et al. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e531S–e575S. doi:10.1378/chest. 11-2304.
2. Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31(19):2369–2429. doi:10.1093/eurheartj/ehq278.
3. Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33(21):2719–2747. doi:10.1093/eurheartj/ehs253.
4. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation. 2014. doi:10.1161/CIR.0000000000000041.
5. Sandhu RK, Bakal JA, Ezekowitz JA, McAlister FA. Risk stratification schemes, anticoagulation use and outcomes: the risk–treatment paradox in patients with newly diagnosed non-valvular atrial fibrillation. Heart. 2011;97(24):2046–2050. doi:10.1136/heartjnl-2011-300901.
6. Mason PK, Lake DE, Dimarco JP, et al. Impact of the CHA(2)DS(2)-VASc Score on Anticoagulation Recommendations for Atrial Fibrillation. Am J Med. 2012;125(6):603 e1-6. doi:10.1016/j.amjmed.2011.09.030.
7. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857–867.
8. Landefeld SC, Beyth R. Anticoagulant-related bleeding: clinical epidemiology, prediction and prevention. Am J Med. 1993;95:315–328.
9. Agarwal S, Hachamovitch R, Menon V. Current trial-associated outcomes with warfarin in prevention of stroke in patients With nonvalvular atrial fibrillation: a meta-analysis. Arch Intern Med. 2012;172(8):623–631. doi:10.1001/archinternmed.2012.121.
10. Jencks SF, Cuerdon T, Burwen DR, et al. Quality of medical care delivered to Medicare beneficiaries: a profile at state and national levels. JAMA. 2000;284(13):1670–1676.
11. Birman-Deych E, Waterman AD, Yan Y, Nilasena DS, Radford MJ, Gage BF. Accuracy of ICD-9-CM codes for identifying cardiovascular and stroke risk factors. Med Care. 2005;43(5):480–485.
12. Gage BF, Yan Y, Milligan PE, et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J. 2006;151(3):713–719.
13. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138(5):1093–1100. doi:10.1378/chest. 10-0134.
14. Singer DE, Chang Y, Fang MC, et al. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med. 2009;151(5):297–305.
15. Gathier CS, Algra A, Rinkel GJ, van der Worp HB. Long-term outcome after anticoagulation-associated intracerebral haemorrhage with or without restarting antithrombotic therapy. Cerebrovasc Dis. 2013;36(1):33–37. doi:10.1159/000351151.
16. Lee. Statistical Methods for Survival Data Analysis. 2nd ed: John Wiley & Sons; 1992.
17. Allison PD. Survival Analysis Using the SAS System: A Practical Guide. Cary, NC: SAS Institute Inc; 1995.
18. Efron B, Tibshirani R. In: Cox DR, Hinkley DV, Reid N, Rubin DB, Silverman BW, eds. An Introduction to the Bootstrap. New York: Chapman & Hall; 1993.
19. Toda E, Lip GYH, Uchiyama S, et al. Sub-analysis of the Japan Thrombosis Registry for atrial fibrillation, coronary or cerebrosvascular events (J-TRACE) [abstract]. J Am Coll Cardiol. 2012;59(13s1):E674-E.
20. Olesen JB, Lip GY, Hansen ML, et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ. 2011;342:d124. doi:10.1136/bmj.d124 bmj.d124.
21. Cha MJ, Oh GC, Hahn S, Choi EK, Oh S. Thromboembolic risk evaluation in patients with atrial fibrillation using a modified CHADS(2) scoring system. J Cardiovasc Electrophysiol. 2012;23(2):155–162. doi:10.1111/j.1540-8167.2011.02181.x.
22. Becattini C, Agnelli G, Schenone A, et al. Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med. 2012;366(21):1959–1967. doi:10.1056/NEJMoa1114238.
23. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285(22):2864–2870.
24. Avgil-Tsadok M, Jackevicius CA, Rahme E, Humphries KH, Behlouli H, Pilote L. Sex differences in stroke risk among older patients with recently diagnosed atrial fibrillation. JAMA. 2012;307(18):1952–1958. doi:10.1001/jama.2012.3490.
25. Olesen JB, Lip GY, Lindhardsen J, et al. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: a net clinical benefit analysis using a ‘real world’ nationwide cohort study. Thromb Haemost. 2011;106(4):739–749. doi:10.1160/TH11-05-0364.
26. Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation. 2007;115(21):2689–2696.
27. Gomes T, Mamdani MM, Holbrook AM, Paterson JM, Hellings C, Juurlink DN. Rates of hemorrhage during warfarin therapy for atrial fibrillation. CMAJ. 2013;185(2):E121-7. doi:10.1503/cmaj.121218.
28. Ghate SR, Biskupiak J, Ye X, Kwong WJ, Brixner DI. All-cause and bleeding-related health care costs in warfarin-treated patients with atrial fibrillation. J Manag Care Pharm. 2011;17(9):672–684.
29. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–1151. doi:10.1056/NEJMoa0905561.
30. Fox KA, Piccini JP, Wojdyla D, et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J. 2011;32(19):2387–2394. doi:10.1093/eurheartj/ehr342.
31. Lip GY, Larsen TB, Skjoth F, Rasmussen LH. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation. J Am Coll Cardiol. 2012. doi:10.1016/j.jacc.2012.03.019.
32. Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364(9):806–817. doi:10.1056/NEJMoa1007432.
33. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–891. doi:10.1056/NEJMoa1009638.
34. Akao M, Chun YH, Esato M, et al. Inappropriate use of oral anticoagulants for patients with atrial fibrillation. Circ J. 2014;78(9):2166–2172.
35. White RH, Beyth RJ, Zhou H, Romano PS. Major bleeding after hospitalization for deep-venous thrombosis. Am J Med. 1999;107(5):414–424.
36. Wahl PM, Rodgers K, Schneeweiss S, et al. Validation of claims-based diagnostic and procedure codes for cardiovascular and gastrointestinal serious adverse events in a commercially-insured population. Pharmacoepidemiol Drug Saf. 2010;19(6):596–603. doi:10.1002/pds.1924.